参考文献/References:
[1] Alsaab H O, Sau S, Alzhrani R, et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mecha-nism, combinations, and clinical outcome[J].Front Pharma-col, 2017,8:561.
[2] Markham A, Keam S J.Camrelizumab: first global approval[J].Drugs, 2019,79(12):1355-1361.
[3] 佘明金.卡瑞利珠单抗治疗恶性肿瘤的临床研究进展[J].癌症进展,2020,18(9):865-869,890.
[4] Song Y, Wu J, Chen X, et al.A Single-arm, multicenter, phase ii study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J].Clin Cancer Res, 2019,25(24):7363-7369.
[5] Huang J, Xu J, Chen Y, et al.Camrelizumab versus inves-tigators choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma(ESCORT): a multicentre, randomised, open-label, phase 3 study[J].Lancet Oncol, 2020,21(6):832-842.
[6] Qin S, Ren Z, Meng Z, et al.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J].Lancet Oncol, 2020,21(4):571-580.
[7] Fang W, Yang Y, Ma Y, et al.Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J].Lancet Oncol, 2018,19(10):1338-1350.
[8] Zhou C, Wang Y, Zhao J, et al.Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced non-squamous NSCLC previously treated with chemotherapy[J].Clin Cancer Res, 2021,27(5):1296-1304.
[9] 秦叔逵,马军,李进,等.卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识[J].临床肿瘤学杂志,2020,25(9):840-848.
[10] Wang F, Qin S, Sun X, et al.Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J].J Hematol Oncol, 2020,13(1):47.